Drug
Furmonertinib
Furmonertinib: highest development phase Phase 1, developed by ArriVent BioPharma, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- ArriVent BioPharma, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| Furmonertinib NCT05364073 | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow Furmonertinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.